Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv
Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre UtrechtFor patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study authorAnton Hagenbeekat the ASH meeting in Atlanta whileGeorge Canellosprovided comment.
Related Episodes
New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia
Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia
NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast